FridaySep 23, 2016 1:19 pm

Laguna Blends, Inc. (LAG) (LAGBF) (LB6A.F) Joins Canadian Securities Exchange Composite Index

Laguna Blends Inc. (CSE: LAG) (OTC: LAGBF) (Frankfurt: LB6A.F) this morning announced its inclusion to the CSE Composite index, reflecting the network marketing company’s aggressive expansion strategy. "Inclusion in the CSE Composite index is another indicator Laguna continues to deliver shareholder value through its strategic growth strategy. Laguna has positioned itself to be a dominant player in the distribution and marketing of unique hemp and CBD related products around the world," Bryan Loree, CFO of Laguna Blends, stated in the news release. Laguna Blends uses a network of independent affiliates to market its hemp-based functional beverages, and is exclusively licensed…

Continue Reading

ThursdaySep 22, 2016 2:09 pm

Terra Tech Corp.’s (TRTC) Edible Garden Begins Shipping Herb Line to Latest Customer

Terra Tech (OTCQX: TRTC), a vertically integrated cannabis-focused agriculture company, this morning announced that its Edible Garden subsidiary has commenced shipping of its line of 4-inch potted living herbs to nationwide supermarket chain Wegmans Food Markets, Inc. Edible Garden is a retail seller of locally grown hydroponic produce, herbs and floral products. Its living potted herbs are USDA-certified organic and without contaminants, pesticides and GMOs. The company says that since Q2 2016 it has more than tripled production of its herb line in response to supermarket demand and increasing popularity among consumers. “As a result of the popularity of this…

Continue Reading

ThursdaySep 22, 2016 2:08 pm

New Jersey Mining Company (NJMC) Discovers New Footwall Vein, Updates on Golden Chest Mine Project

Idaho-based New Jersey Mining Company (OTCQB: NJMC) this morning reported its discovery of a new footwall vein (the “Stevens Vein”). Pit excavation revealed three veins in the pit area: a hanging wall vein thought to be the Jumbo vein, the Idaho vein, and the Stevens Vein. On the 1096 bench, trench sampling has shown the Stevens Vein and the Idaho Vein to be at least three meters wide with a grade of 15.2 grams per tonne (gpt) gold, and approximately two meters (true thickness) with a grade of 4.0 gpt gold, respectively. The company also provided an update on open…

Continue Reading

ThursdaySep 22, 2016 2:03 pm

Antares Pharma, Inc. (ATRS) Reports Safety Data from QuickShot Testosterone Clinical Program

Antares Pharma (NASDAQ: ATRS) today announced 26-week safety data from the phase 3 study of QuickShot® Testosterone (QST) administered subcutaneously once each week to adult males with hypogonadism.  The study, QST-15-005, showed that the most common adverse reactions (incidence ≥5%) were increased hematocrit, upper respiratory tract infection and injection site ecchymosis.  The company reports four patients with treatment emergent serious adverse events (SAEs), which included one patient with transient visual impairment determined not to be drug related; one patient with appendicitis that was not drug related; one patient with deep vein thrombosis (DVT), which the investigator attributed DVT as possibly…

Continue Reading

ThursdaySep 22, 2016 1:59 pm

Anavex Life Sciences Corp. (AVXL) Presents Positive Initial Data for Parkinson’s Disease Drug Candidate

At the World Parkinson Congress 2016 in Portland earlier today, Anavex Life Sciences (NASDAQ: AVXL) presented preclinical data in a poster titled “Investigating the potential neurorestorative effects of a clinical Sigma-1 receptor agonist in a mouse model of Parkinson’s disease.” Initial data demonstrated that the company’s ANAVEX 2-73, a sigma-1 receptor agonist, restores function in a classic animal model of Parkinson’s disease. The company reports “significant” improvements across the board, including behavioral, histopathological, and neuroinflammatory endpoints. “This initial data is encouraging, and together with already available clinical safety and tolerability data on ANAVEX 2-73, might accelerate the exploration of ANAVEX…

Continue Reading

ThursdaySep 22, 2016 1:55 pm

MagneGas Corporation (MNGA) Hits Corporate Milestone with Construction of Gasification System

MagneGas (NASDAQ: MNGA) this morning announced that it has completed construction of the Plasma-Arc Gasification system – a move company CEO Ermanno Santilli calls “the single most important event of the year.” Under the previously announced “Gasifier Agreement,” Green Arc Supply, LLC is contracted to purchase the system and thus far has paid a total of $583,750 toward construction of the system. Upon final payment of $191,500, expected in the next 30 days pending factory acceptance, Green Arc will have exclusive distribution rights to MagneGas2® for certain regions of Louisiana and Texas, as well as non-exclusive distribution rights in remaining…

Continue Reading

WednesdaySep 21, 2016 2:02 pm

Peregrine Pharmaceuticals, Inc. (PPHM, PPHMP) Issues Update on Presentation of Top-Line Data at European Society for Medical Oncology

Peregrine Pharmaceuticals (NASDAQ: PPHM, PPHMP) reports that it will present top-line data from the phase 3 SUNRISE trial of its bavituximab cancer treatment as a late-breaking oral presentation at the upcoming European Society for Medical Oncology (ESMO) 2016 Congress. The company will present data showing that a biomarker in the SUNRISE trial correlated with a statistically significant improvement in overall survival for patients treated with bavituximab in combination with docetaxel compared to patients treated with docetaxel alone. Peregrine will file a new patent application directed to the use of the biomarker prior to the presentation of results at the ESMO…

Continue Reading

WednesdaySep 21, 2016 1:58 pm

Xplore Technologies Corp. (XPLR) Successfully Completes Compatibility Testing of XSLATE D10 Fully Rugged Tablet

Xplore Technologies (NASDAQ: XPLR) has completed the MobileIron Android Self Testing Program, confirming that its XSLATE D10 fully rugged tablet PC is compatible with Android for Work in MobileIron’s (NASDAQ: MOBL) mobile device management (MDM) environment. The testing program is designed for manufacturers to verify whether their devices support the Google standard APIs, which are used by MobileIron to enable password policies, encryption, certificate management and other enterprise features. To view the full press release, visit: http://nnw.fm/3nW4h About Xplore Technologies Corp. Xplore is The Rugged Tablet Authority, exclusively manufacturing powerful, long-lasting, and customer-defined rugged tablet PCs since 1996. Today, Xplore…

Continue Reading

WednesdaySep 21, 2016 1:54 pm

Skyline Medical, Inc. (SKLN) Partners with GLG Pharma to Develop Oncology Test Panels

Skyline Medical (NASDAQ: SKLN), producer of the FDA-approved STREAMWAY System for automated, direct-to-drain medical fluid disposal, has entered into an exclusive reseller agreement in which GLG Pharma, LLC intends to develop rapid diagnostic tests that utilize fluid and tissue collected by the STREAMWAY System during procedures. Per the agreement, Skyline will issue common stock to GLG Pharma in four separate tranches, with each tranche released after the achievement of certain development milestones. In addition, Skyline will pay a royalty to GLG on the sale of individual tests. To view the full press release, visit: http://nnw.fm/CgH4x About Skyline Medical, Inc. Skyline…

Continue Reading

WednesdaySep 21, 2016 1:50 pm

Eleven Biotherapeutics, Inc.’s (EBIO) Acquisition of Viventia Bio Creates Targeted Protein Therapeutics Oncology Company

Through a share purchase agreement, Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) has acquired Viventia Bio, Inc., creating a single entity focused on the development of novel treatments in areas of oncology with significant unmet need. In addition to other drug candidates, Eleven’s pipeline now includes Viventias’ two lead product candidates: Vicinium, in a phase 3 clinical trial for high-grade non-muscle invasive bladder cancer (NMIBC), with topline data expected in the first half of 2018; and Proxinium, expected to enter phase 2 development in early 2017 for the treatment of late-stage squamous cell carcinoma of the head and neck. To view the…

Continue Reading

Contact us: 212.418.1217